«Development of noninvasive tests to detect immune activation before kidney damage occurs would help guide the care of kidney transplant recipients,» said NIAID
Transplantation Branch Chief Nancy Bridges, M.D., a co-author of the paper.
«This is the first license - enabling trial of a cellular product for treatment of type 1 diabetes,» said NIAID
Transplantation Branch Chief Nancy D. Bridges, M.D., a co-author of the paper.